Costello J, Njue A, Lyall M, Heyes A, Mahler N, Philbin M, Nazareth T. Efficacy, safety, and quality-of-life of treatments for acute relapses of multiple sclerosis: results from a literature review of randomized controlled trials. Degener Neurol Neuromuscul Dis. 2019 Jul 1;9:55-78. doi: 10.2147/DNND.S208815
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Garcia-Albeniz X, Martinez-Fernandez A, Gascon P. Combining targeted therapies. Target Oncol. 2007 Oct;2(4):241-52. doi: 10.1007/s11523-007-0062-5
Milunsky A, Morris JS, Jick H, Rothman KJ, Ulcickas M, Jick SS, Shoukimas P, Willett W. Maternal zinc and fetal neural tube defects. Teratology. 1992 Oct 1;46(4):341-8.
Rothman KJ, Fyler DC. Association of congenital heart defects with season and population density. Teratology. 1976 Feb;13(1):29-34.